What is the price target for IPSC stock?
12 analysts have analysed IPSC and the average price target is 4.2 USD. This implies a price increase of 108.04% is expected in the next year compared to the current price of 2.02.
CENTURY THERAPEUTICS INC (IPSC) Forecast, Price Target & Analyst Ratings
NASDAQ:IPSC • US15673T1007
Current stock price
2.02 USD
-0.04 (-1.94%)
At close:
2 USD
-0.02 (-0.99%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CENTURY THERAPEUTICS INC (IPSC).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.17
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.20
Upside
+ 108.04%
From current price of $2.02 to mean target of $4.20, Based on 12 analyst forecasts
Low
$2.02
Median
$4.08
High
$6.93
Price Target Revisions
1 Month
0.00%
3 Months
3.00%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for IPSC. The average price target is 4.2 USD. This implies a price increase of 108.04% is expected in the next year compared to the current price of 2.02.
The average price target has been revised upward by 3% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
IPSC was analyzed by 12 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about IPSC.
In the previous month the buy percentage consensus was at a similar level.
IPSC was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-20 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-11-17 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-05-16 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-28 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-24 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-21 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-20 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-01-22 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-30 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-06-17 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-06-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-12 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-03-15 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-03-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-28 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-08-10 | EF Hutton | Reiterate | Buy -> Buy |
| 2023-08-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-08-10 | Piper Sandler | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.17
- Revenue Estimate
- Revenue Q2Q
- -100.00%
- EPS Q2Q
- -119.20%
- Number of Analysts
- 7
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
16.25%
EPS (3 Months)
16.25%
Next Earnings Summary
IPSC is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.17 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.235M -57.02% | 6.589M 194.81% | 109.164M 1,556.76% | -100.00% | 17.85M | 43.35M 142.86% | ||||||
| EBITDA YoY % growth | -112.137M 2.82% | -120.506M -7.46% | 2.595M 102.15% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -125.181M -1.09% | -133.81M -6.89% | -10.506M 92.15% | -107.25M -920.85% | -121.482M -13.27% | -154.034M -26.80% | -178.5M -15.88% | -196.35M -10.00% | 650.76M 431.43% | N/A | N/A | |
| Operating Margin | -5,600.94% | -2,030.81% | -9.62% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -2.29 -0.88% | -1.63 28.82% | -0.03 98.16% | -0.59 -1,855.00% | -0.55 5.51% | -1.31 -135.58% | -0.51 60.94% | -0.51 | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.17 -119.20% | -0.21 43.63% | -0.22 29.87% | -0.23 -4.32% |
| Revenue Q2Q % growth | -100.00% | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -27.608M -137.22% | -25.755M 25.70% | -26.52M 9.68% | -27.795M -34.59% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-251.75%
EPS Next 5 Year
-76.23%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
-14.87%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
CENTURY THERAPEUTICS INC / IPSC Forecast FAQ
Can you provide the upcoming earnings date for CENTURY THERAPEUTICS INC?
CENTURY THERAPEUTICS INC (IPSC) will report earnings on 2026-05-04, before the market open.
What are the consensus estimates for CENTURY THERAPEUTICS INC (IPSC) next earnings?
The consensus EPS estimate for the next earnings of CENTURY THERAPEUTICS INC (IPSC) is -0.17 USD and the consensus revenue estimate is 0 USD.
What is the number of analysts for IPSC stock?
The number of analysts covering CENTURY THERAPEUTICS INC (IPSC) is 12.